# A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

> **NCT04007536** · — · COMPLETED · sponsor: **Denali Therapeutics Inc.** · enrollment: 18 (actual)

## Conditions studied

- Mucopolysaccharidosis II

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT04007536
- **Lead sponsor:** Denali Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-23
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04007536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04007536, "A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04007536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*